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Microscale coiling in bis-imidazolium supramolecular hydrogel 
fibres induced by release of a cationic serine protease inhibitor  
David Limón,a,b Claire Jiménez-Newman,a Ana C. Calpena,b,c Arántzazu González-Campo,d David B. 
Amabilino,e,f and Lluïsa Pérez-García.a,b,‡ ,*
Gels formed by a gemini dicationic amphiphile incorporate a serine 
protease inhibitor, which could be used in a new approach to the 
treatment of Rosacea, within the fibres as well as in the space 
between them, affecting a number of gel properties but most 
importantly inducing remarkable fibre coiling at the microscopic 
level as a result of drug release from the gel. Drug release and skin 
permeation experiments show its potential for topical 
administration. 
Low molecular weight gelators (LMWGs) self-assemble to form 
fibres through non-covalent forces.1 These supramolecular gels 
are soft and sometimes thermoreversible, making them 
suitable for therapeutic applications.2 Their three-dimensional 
morphology depends on the nature of the gelator, the self-
assembly conditions, and non-covalent interactions established 
with host molecules incorporated into the gel matrix, like, ion-
dipole interactions in metal and anion-binding gels.3 Also, gel 
skeletal modification can be made introducing metal ions.4 
However, to the best of our knowledge, no examples are known 
of changes in the morphology of the gel fibres caused by the 
release of a previously incorporated host. 
 Our group has shown that gemini imidazolium salts can 
deliver anionic drugs,5 including from hydrogels that are useful 
for topical applications.6 The self-assembly of the cationic 
gelators and the interaction with anionic guests in the 
supramolecular gels is driven not only by ionic interactions but 
also hydrogen bonds and hydrophobic forces.6 Here, we show 
that the incorporated drug can also be cationic, that this feature 
makes drug release more effective, leading to a change in the 
morphology of the cationic gels through coiling of the gel fibres. 
 We chose the drug 4-(2-aminoethyl)-benzenesulfonyl 
fluoride hydrochloride (AEBSF·HCl), as an irreversible serine 
protease inhibitor whose activity has shown to be successful, 
inhibiting Kallikrein-5 (K5),7 a protein that is overexpressed in 
ailments such as Rosacea.8 Its clinical use would imply a new 
therapeutic strategy that has not been reported, the main 
drawback being low drugability. A delivery material could 
overcome this obstacle and make a novel approach in the 
topical treatment of Rosacea. Furthermore, topical 
administration helps increase the drug concentration at the 
target site, lowering the side effects in other tissues. 
 For all these reasons, the ability of bis-imidazolium 1·2Br to 
form gels in presence of AEBSF·HCl (Fig. 1) using water and 
ethanol as solvents was explored and the gelling conditions 
were optimized. The structure and behaviour of the gels were 
characterized, and drug release and skin permeation 
experiments were performed in order to assess their suitability 
as a possible new topical treatment for Rosacea. 
 The optimum gelling conditions of compound 1·2Br are a 
final concentration of 5 mg/mL in 50:50 ethanol:water, and at 
room temperature, giving a fast gel formation (ca. 10 min.). The 
influence of AEBSF·HCl concentration was assessed using these 
optimized conditions. Gels 1·AEBSF are also formed in 10 
minutes in the presence of low concentrations of drug, but the 
gelling time increased significantly at higher concentrations 
(above 4 mg/mL, See ESI Fig. S1). A final concentration of 5 
mg/mL AEBSF·HCl was chosen as optimum for being the highest 
one that permits gelation in 20 minutes or less. This proportion 
is an approximate 1:4 gelator:drug molar ratio, a much higher 
loading than that possible using the same gelator and anionic 
drugs.6 
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Fig. 1 Chemical structures of the gelator 1·2Br and the serine protease inhibitor 
AEBSF·HCl. 
 Rheological studies of gels 1·2Br and 1·AEBSF show their 
resistance to rupture by the critical stress value: the addition of 
AEBSF·HCl makes the gel three times more elastic as compared 
to the gel alone (ESI Table S1 and Fig. S2), as opposed to the 
observations with other drugs.6b However, when the critical 
stress is reached, gels show an abrupt rupture rather than a 
slow one, making it suitable for a topical pharmaceutical form. 
Frequency sweep tests showed the gel resistance to 
deformation at different frequencies, shown by the Storage (G’) 
and Loss (G’’) moduli, at a constant shear stress of  = 0.5 Pa for 
being within the viscoelastic region. In both the gel 1·AEBSF and 
the gel 1·2Br, independently of the frequency applied, an elastic 
plateau was observed, where the Storage modulus is higher 
than the Loss modulus (G’ > G’’), meaning that gels present a 
predominant elastic, solid-like behaviour, for which they can be 
classified as “solid-like” gels.1a,9  The addition of AEBSF·HCl 
decreases the gel resistance to deformation, making it softer 
than gel 1·2Br which is also useful for topical application (ESI Fig. 
S2). 
 1H NMR spectroscopy experiments show (ESI Fig. S3) that at 
a 1:1 molar ratio of 1·2Br and AEBSF·HCl (5:1 mg/mL) the 
totality of 1·2Br assembles forming the gel 1·AEBSF, leaving no 
remaining compound in solution, as no peaks from compound 
1·2Br can be observed. Ca. 76% of the AEBSF·HCl present in the 
mixture is incorporated in the gel fibres, the remainder left in 
the interstitial space.  The versatility of the gelator 1·2Br to 
incorporate both anionic and cationic drugs confirms its 
promise for drug delivery. 
 Xerogel 1·2Br has fibres longer than 20 μm and around 100 
nm width, that stick together forming ribbons and do not show 
signs of ageing (Fig. 2a and Fig. S4a in ESI). Contrastingly, the 
morphology of the gels 1·AEBSF changes with time, a 
phenomenon which is also dependent on the concentration of 
AEBSF·HCl used (ranging from 1-5 mg/mL). AEBSF precipitates 
might be expected after complete evaporation of the solvent in 
the gel, because even at 1 mg/mL 24% of the material is in the 
interstitial space (as shown by NMR); pure AEBSF·HCl 
precipitates in rod-shaped crystals (Fig. 2b). In all gels with 
1·AEBSF, no clear drug precipitates were found on freshly 
prepared gels, when gelation takes place in the presence of 
either 1, 3 or 5 mg/mL of AEBSF·HCl, as shown by SEM images 
(Fig. 2c and ESI Fig. S5). It is interesting that fibres in 1·AEBSF 
are densely twisted much more than pure gel 1·2Br, which could 
be the reason of their subsequent coiling in order to reduce the 
tension created. 
 
Fig. 2 SEM images showing the influence of drug concentration and age of the gel on 
the morphology of gel fibres. a) Gel 1·2Br. b) Precipitates of AEBSF·HCl, from a 5 mg/mL 
solution. c) Freshly prepared 1·AEBSF gel. d) Influence of the drug concentration in a 
two-week old gel. Yellow scale bar represents 8 μm in all images. 
 When gels 1·AEBSF are left for two weeks in a sealed vial the 
morphology of the xerogels exhibits changes depending of the 
amount of AEBSF·HCl present in the gelation process.  Thus, 
when 1mg/mL of AEBSF·HCl was used, the fibres in 1·AEBSF 
retain the same morphology as when freshly prepared, as seen 
in Fig. 2d (see also ESI Fig. S5a). In contrast, in the two-week old 
gels formed at a concentration above 3 mg/mL of AEBSF·HCl, 
the bending of the fibres in a circular way, resembling “coiled 
Gel 1·AEBSF    Two-week old
1 mg/mL 3 mg/mL
3 mg/mL
5 mg/mL5 mg/mL
3 mg/mL
d
Gel 1·2Br    Two-week olda
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ropes” can be observed (Fig. 2d, ESI Fig. S4b, Fig. S5a). These 
rolls range from 5 to 15 μm in diameter, and the thickness of 
the ring varies widely due to the number of times the “rope” is 
coiled. As can be seen, the concentration of AEBSF·HCl 
influences the structure of fibres in two-week old gels 1·AEBSF. 
Coils were formed both at 3 and 5 mg/mL gels, the coils being 
thinner at 3 mg/mL, as fibres are coiled less times. Also, at this 
concentration some long straight fibres are still starting to bend, 
suggesting the subsequent coil formation. 
 Just a few examples of differences in morphology of 
nanostructured materials have been reported before,10 but 
mainly as the consequence of induced self-assembly after 
evaporation, and very rarely as a result of doping gels with 
metal ions.4 The coiling observed on the fibres of 1·AEBSF 
appears as an unprecedented example of ordering 
rearrangement induced by intermolecular interactions. Thus, 
the cationic drug AEBSF·HCl seems to be kinetically entrapped 
within the gel nanostructure, due to the fast self-assembly in 
the gelation process, generating a metastable state where the 
drug is incorporated in the lamellar gel. However, its presence 
disturbs the interlayer packing of the gelator 1·2Br that can 
experiment alterations upon changes in external experimental 
conditions. 
 The chemical composition of the fibres was measured by 
Energy Dispersive X-ray spectroscopy (EDX) on different areas 
of two-week old 1·AEBSF xerogels assembled in the presence of 
3 mg/mL (ESI Fig. S6) or 5 mg/mL (Fig. 3) of AEBSF·HCl. The 
spectra show the presence of sulphur in the straight fibres in 
gels for both concentrations, confirming the presence of the 
drug after two weeks. However, in the coiled fibres the absence 
or diminution of both the sulphur and fluorine peaks suggests 
that there is release of drug from the fibres over time, 
presumably into the interstitial liquid. The release could trigger 
the disruption in the interlayer packing within the fibres, 
prompting their coiling. 
 Differential Scanning Calorimetry (DSC) showed that the 
time needed for gel formation of 1·AEBSF and the thermodyna 
 
Fig. 3 EDX spectra from straight fibre and coiled fibre of 5 mg/mL 1·AEBSF gel. 
mic parameters associated with the phase transition are very 
different to gel 1·2Br.  The addition of AEBSF·HCl to gelator 
1·2Br influences greatly the gelling temperature (Fig. S7 in ESI), 
time of gelation, and associated enthalpy change. Gel 1·2Br 
spontaneously starts forming at around 21 °C, while gel 1·AEBSF 
starts forming at ca. 30 °C. This shows that adding the drug 
makes the gel more stable at higher temperatures. Conversely, 
the whole width of the peak indicates the total time for gel 
formation, which increases considerably from around 5 min to 
20 min by adding AEBSF·HCl, similar to the observations with 
the naked eye, and suggesting that the interaction between the 
drug and the gelator lengthens the gelling period, presumably 
because of slower gel fibre assembly. The heat capacity (Cp) in 
the plot also represents the speed of gelation, where the onset 
temperature is the point at which gelation starts, and the 
maximum value is when the gelation occurs fastest. For 
instance, the gelation of 1·AEBSF is 20 times slower than that of 
gel 1·2Br, which is in accordance to the increase in the gelling 
period. 
 The most noticeable change observed is in the 
thermodynamic parameters of the process. The gelation of 
1·2Br is exothermic, and is related to the decrease of entropy 
upon the formation of fibres. Very differently, the gelling of 
1·AEBSF shows both an exothermic event in the beginning, and 
an endothermic one at lower temperatures, giving an overall 
enthalpy close to zero. These results indicate that upon the 
mixture of 1·2Br with AEBSF·HCl and the solvents, not only the 
gelation occurs, but at least a second process is happening at 
the same time, which is endothermic, and therefore, necessarily 
entropic. This event could be an adsorption of the drug in the 
interstitial space of the gel to the fibres, and might be related to 
an increase in the surface tension of the solvent. The 
thermoreversibility of 1·AEBSF was proven by subsequent 
heating-cooling cycles, in order to melt the gel and form it again, 
and similar peaks were observed. However, a slight decrease in 
Cp values, and a slight increase in the gelling temperature, occur 
in each cycle, which suggests that heating up the sample to 35 
°C melts the gel but still leaves some gel nucleation points 
intact, not seen macroscopically, which facilitate the 
subsequent gelation on cooling (ESI, Table S2 and Fig. S8). 
 Drug release experiments from the nanocomposite material 
using PBS as the receptor medium for complying SINK 
conditions,11 to prove of the drug when applied on human skin 
is not limited, showed that gel 1·AEBSF releases almost 92% of 
the drug during the first 15 hours (fitting a one phase 
exponential association model). Afterwards, drug degradation 
occurs in the receptor chamber,12 following a one phase 
exponential decay model (Fig. 4 and Table S3). This degradation 
would not compromise the therapeutical efficacy of the gel 
when applied on the skin, as the speed of release is ten times 
higher than the speed of degradation, whose half-life (55 h) is 
much longer than the usual administration intervals of topical 
formulations. Moreover, at the normal pH of the skin (5.5), 
degradation would barely occur. Permeation studies on human 
skin show that 1·AEBSF promotes the complete permeation of 
AEBSF through the skin in 6 hours (lag-time, see Fig. 5 and ESI 
Table S4). 
As K5 is located mainly at the epidermis, specifically at the 
cornified and granular layers,13,14 the amount of drug retained 
inside the skin becomes an even more important parameter to 
be considered. The total amount of AEBSF retained (As corr.) is 
estimated by considering both the amount of drug extracted 
from the skin after the experiment [As] and the percentage of 
drug that can actually be extracted out of the total drug 
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retained (recovery experiments). After topical application, 
around 3484 µg/g·cm2, is retained in the skin, where it has its 
therapeutic activity, equivalent to 69% of the total dose applied 
(Fig. 5). 
 
Fig. 4. Cumulative amount of drug released of from gel 1·AEBSF and degradation in 
receptor medium. Values are means and error bars represent one standard deviation 
(n=3). Release and decay both follow one phase exponentials (see ESI and equation 
parameters in Table S3).  
 
Fig. 5. Cumulative amount of AEBSF permeated (left) and retained in human skin (right) 
after application of gel 1·AEBSF. Values in permeation experiments represent the Means 
± one standard deviation. The bar in retention experiments represents the Median value 
(n=5). 
 Changes in the morphology of the gels were scrutinized by 
SEM after being subjected to release conditions, for a maximum 
of 16 h, the maximum period permitting almost a total release 
with no detectable hydrolysis of the drug. In all the samples, 
some lumpy material arises from the buffer used under those 
conditions. No variation was observed for the pure gel 1·2Br, for 
which only straight fibres were seen (Fig. S9 in ESI). The release 
of the drug from 1·AEBSF under these release conditions for  6 
and 16 hours is also accompanied by the formation of fibre coils 
(see SEM images in ESI Fig S9 and S10). The images clearly show 
the formation of coils and a more structured and curved nature 
to the fibres of the gelator. Direct quantification is not possible, 
but the number of coiled fibres seems similar to those on aged 
gels under storage conditions over a longer period of time. 
While the morphological change is clear, powder X-ray 
diffraction of gels before and after release shows no significant 
structural rearrangement (Fig. S11 in ESI). A model such that in 
Fig. S12 might explain this observation. 
 In summary, AEBSF·HCl strongly influences the self-
assembly of 1·2Br and the behaviour of the resulting gel, which 
is soft and thus suitable for dermal application. AEBSF is 
released from the gel, triggering its morphological change 
evidenced by the twisting of fibres and the subsequent 
formation of coils, although not all fibres are able to coil, 
presumably because their length and being trapped physically 
by other fibres. Almost all the drug incorporated in 1·AEBSF is 
released and penetrates human skin, where it is retained. By the 
nature of the drug incorporated, this gel would imply a novel 
therapeutic approach in the topical treatment of ailments like 
Rosacea. 
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